Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Completed · Phase 2 · NCT05616013
Conditions: Obesity, Obese, Overweight or Obesity
At a glance
- Research payments reported, 2025
- $281
- U.S. investigators named
- 3
- Sites paid
- 1
- Planned or actual enrollment
- 507
About the trial
- Sponsor
- Eli Lilly and Company (with Versanis Bio, Inc.)
- Tested
- Bimagrumab (biological), Semaglutide (drug), Placebo (other)
- Dates
- Started 2022-11-16; completion 2025-06-14
- Results posted
- Yes
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $281 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.